<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Entecavir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00442</strong>&#160; (APRD00948)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (<span class="caps">BMS</span>).</p>
<p>Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (<span class="caps">FDA</span>) in March 2005.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00442/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00442/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00442.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00442.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00442.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00442.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00442.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00442">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Entecavir</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Entecavirum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Baraclude</td><td>Bristol-Myers Squibb</td></tr><tr><td>Barcavir</td><td>Incepta</td></tr><tr><td>Caavirel</td><td>PMP</td></tr><tr><td>Entaliv</td><td>Dr. Reddy's Laboratories</td></tr><tr><td>Teviral</td><td>ACI</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Emtriva</td><td>Entecavir and Emtricitabine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>142217-69-4</td></tr><tr><th>Weight</th><td>Average: 277.2792<br>Monoisotopic: 277.117489371</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>15</sub>N<sub>5</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>QDGZDCVAUDNJFG-FXQIFTODSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Purine Nucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Hypoxanthines; Pyrimidones; Primary Aromatic Amines; N-substituted Imidazoles; Secondary Alcohols; Cyclic Alcohols and Derivatives; Polyamines; Primary Alcohols</td></tr><tr><th>Substituents</th><td>hypoxanthine; purinone; imidazopyrimidine; purine; pyrimidone; primary aromatic amine; n-substituted imidazole; pyrimidine; cyclic alcohol; imidazole; azole; secondary alcohol; polyamine; primary alcohol; amine; primary amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</td></tr><tr><th>Pharmacodynamics</th><td>Entecavir is a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process. Entecavir is more efficient than an older Hepatitis B drug, lamivudine.</td></tr><tr><th>Mechanism of action</th><td>By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity.</td></tr><tr><th>Absorption</th><td>Absorption Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. In healthy subjects, the bioavailability of the tablet is 100% relative to the oral solution.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Binding of entecavir to human serum proteins in vitro is approximately 13%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Entecavir is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP450) enzyme system. Entecavir is efficiently phosphorylated to the active triphosphate form.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128-149 hours. The phosphorylated metabolite has a half-life of 15 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>renal cl=383.2 +/- 101.8 mL/min [Unimpaired renal function]</li>
	<li>renal cl=197.9 +/- 78.1 mL/min [Mild impaired renal function]</li>
	<li>renal cl=135.6 +/- 31.6 mL/min [Moderate impaired renal function]</li>
	<li>renal cl=40.3 +/- 10.1 mL/min [severe impaired renal function]</li>
	<li>apparent oral cl=588.1 +/- 153.7 mL/min [Unimpaired renal function]</li>
	<li>apparent oral cl=309.2 +/- 62.6 mL/min [Mild impaired renal function]</li>
	<li>apparent oral cl=226.3 +/- 60.1 mL/min [Moderate impaired renal function]</li>
	<li>apparent oral cl=100.6 +/- 29.1 mL/min [severe impaired renal function]</li>
	<li>apparent oral cl=50.6 +/- 16.5 mL/min [severe impaired renal function amnaged with Hemodialysis]</li>
	<li>apparent oral cl=35.7 +/- 19.6 mL/min [severe impaired renal function amnaged with <span class="caps">CAPD</span>]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Healthy subjects who received single entecavir doses up to 40 mg or multiple doses up to 20 mg/day for up to 14 days had no increase in or unexpected adverse events. If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.</td></tr><tr><th>Affected organisms</th><td><ul><li>Hepatitis B virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.873</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7601</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5802</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.863</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9185</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8465</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8817</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8164</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5346</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7641</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.848</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.915</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.87</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9647</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9552</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7523
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8026
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9669
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3879 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8865
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9062
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>E.R. Squibb and Sons LLC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>